CLEO Diagnostics LtdASX: COV

CLEO Screening Test Meets Rigorous Performance Targets

· Issued by CLEO Diagnostics Ltd via ASX

Filed with ASX · · 4 pages · English

Summary by 6ix AI

Cleo Diagnostics Ltd has announced that its prototype ovarian cancer screening test has successfully met and exceeded performance targets in its first proof-of-concept study involving a cohort of individuals. The study demonstrated high sensitivity and specificity for both high-risk and general populations, particularly for early-stage cancers, which are crucial for improving survival rates. Cleo plans to advance its screening development program with further studies to confirm these initial results and assess the test's performance in broader populations.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

ASX Announcement CLEO Screening Test Meets Rigorous Performance Targets in First Proof-of- Concept Study Highlights • Prototype Screening Test has met and exceeded its pre-de?ned performance thresholds in its ?rst proof-of-concept study of 247 individuals • In a cohort enriched with 62 Stage I...

CLEO Diagnostics Ltd on 6ix

Earlier from CLEO Diagnostics

Later from CLEO Diagnostics

All CLEO Diagnostics news releases